Cadila Healthcare Latest News
-
Pursuant to Regulation 39(3) of the SEBI Listing Regulations, Cadila Healthcare has informed that it has received the information of loss of share certificate and request for issue of duplicate share certificate fro...
Date:27-02-2021 -
Zydus Cadila has got final approval from USFDA to market Nortriptyline Hydrochloride CapsulesDate:26-02-2021
-
Zydus Cadila has received final approval from USFDA to market Nortriptyline Hydrochloride CapsulesDate:25-02-2021
-
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, AhmedabadDate:25-02-2021
-
Zydus Cadila has received final approval from USFDA to market Droxidopa CapsulesDate:24-02-2021
-
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, AhmedabadDate:19-02-2021
-
Cadila Healthcare has informed that it has enclosed the Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express.
Th...
Date:10-02-2021 -
Total consolidated income of the company increased by 4.51% at Rs 3,823.10 crore for Q3FY21Date:08-02-2021
-
Total consolidated income of the company increased by 4.51% at Rs 3,823.10 crore for Q3FY21Date:06-02-2021
-
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysisDate:05-02-2021
SEBI Registered: Investment Adviser - 
+91 20 6725 8333